Challenges in the Management of VIPoma Patients Abstract #244

Introduction: VIPomas are a rare neuroendocrine tumor (NET). 90% are pancreatic. 40-70% are metastatic at presentation. The VIPoma syndrome is characterized by secretory diarrhoea, hypokalaemia and achlorhydria.
Aim(s): To review the complexities of management and outcome in a case series of six VIPoma patients with long-term follow-up.
Materials and methods: A retrospective study of six VIPoma patients (two male, four female; age 33-72 years at presentation) was performed. Diagnosis was based on the presence of compatible symptoms, plasma VIP levels, imaging and histopathology. Clinical management and course was reviewed. Follow-up was complete in all patients (range 72 – 168 months, median 84 months).
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Fatima El-Khouly

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1106 Salvage Treatment with Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Advanced VIPomas and Severe Verner-Morrison Syndrome
Introduction: PRRT is an effective treatment option for advanced Neuroendocrine Tumours
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: Dr Mehmet Yalchin
Keywords: PRRT VIP
#251 Ki-67 is a Better Prognostic Marker than Mitotic Count in Neuroendocrine Tumors
Introduction: The recent classification system proposed by ENETS assigns grade by Ki-67 index +/- mitotic count. It has been adopted into routine practice but there is limited data on the relationship between them.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Mohid S Khan
#130 Lanreotide Autogel for malignant carcinoid syndrome: an 8-year experience
Introduction: Somatostatin analogues provide symptomatic relief in carcinoid syndrome and recently have been shown to inhibit tumor growth in metastatic gastroenteropancreatic neuroendocrine tumors (NETs). Lanreotide compounds are reported to have similar efficacy to Octreotide compounds. There is limited long-term data available on Lanreoitde Autogel.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohid S Khan
#243 Morbidity and Mortality Associated with Desmoplasia in Midgut Neuroendocrine Tumors (NETs)
Introduction: The clinical course of midgut NETs may be heavily complicated by problems related to mesenteric desmoplasia, causing symptoms secondary to mesenteric artery/vein occlusion and bowel obstruction.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Fatima El-Khouly
#252 Y90-DOTATATE in Gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Survival Following Different Indications for Treatment
Introduction: Peptide Receptor Radionuclide Therapy (PRRT) is an increasingly used treatment for GEP -NETs but there is limited data on indications, efficacy and survival.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Mohid S Khan